ArticleCNS neuroscience & therapeutics2025

Comparative Efficacy and Safety of Extended Versus Standard Interval Dosing of Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Analysis.

Meral Seferoğlu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.